CSM Advisors LLC Has $5.45 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

CSM Advisors LLC cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 7.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 59,005 shares of the biopharmaceutical company's stock after selling 4,760 shares during the period. CSM Advisors LLC's holdings in Gilead Sciences were worth $5,448,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the business. Westside Investment Management Inc. increased its holdings in Gilead Sciences by 3.5% in the third quarter. Westside Investment Management Inc. now owns 27,443 shares of the biopharmaceutical company's stock valued at $2,249,000 after purchasing an additional 917 shares during the last quarter. SkyView Investment Advisors LLC boosted its stake in Gilead Sciences by 5.4% during the 3rd quarter. SkyView Investment Advisors LLC now owns 8,482 shares of the biopharmaceutical company's stock worth $711,000 after acquiring an additional 435 shares during the last quarter. Pine Valley Investments Ltd Liability Co acquired a new position in Gilead Sciences during the third quarter valued at approximately $209,000. World Investment Advisors LLC raised its holdings in Gilead Sciences by 33.6% in the third quarter. World Investment Advisors LLC now owns 25,999 shares of the biopharmaceutical company's stock worth $2,180,000 after purchasing an additional 6,535 shares during the period. Finally, Arvest Bank Trust Division bought a new position in shares of Gilead Sciences during the third quarter worth $9,661,000. Institutional investors own 83.67% of the company's stock.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $104.09, for a total value of $260,225.00. Following the transaction, the chief financial officer now directly owns 169,061 shares of the company's stock, valued at $17,597,559.49. This trade represents a 1.46 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 302,785 shares of company stock worth $30,540,875 in the last quarter. 0.27% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Morgan Stanley raised their price objective on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research note on Friday. DZ Bank upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price target for the company in a report on Thursday, February 13th. The Goldman Sachs Group raised their price objective on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a report on Wednesday, February 12th. BMO Capital Markets increased their target price on Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a report on Wednesday, February 12th. Finally, Wells Fargo & Company upped their price objective on Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Nine investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $108.42.

Gilead Sciences Stock Performance

GILD stock traded down $2.98 during mid-day trading on Friday, hitting $103.17. 14,207,970 shares of the company were exchanged, compared to its average volume of 7,526,289. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96. The stock has a market capitalization of $128.46 billion, a PE ratio of 278.84, a price-to-earnings-growth ratio of 0.71 and a beta of 0.32. The business has a 50 day simple moving average of $109.21 and a 200-day simple moving average of $98.15. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.73 by $0.08. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The business had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. During the same period last year, the firm posted ($1.32) EPS. On average, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 3.06%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences's dividend payout ratio is 854.05%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.